AMGN vs BIIB
Amgen Inc (AMGN) and Biogen Inc. (BIIB) are both filed with the SEC under Biological Products, (No Diagnostic Substances). AMGN is 7.2× BIIB's size by market cap ($236.3B against $32.7B); AMGN trades at the higher fiscal-year P/E (30.7× against 25.2×); AMGN reports the higher net margin (21.0% against 13.1%); AMGN grew sales faster over three years (+11.8% against -0.9%); and over the past year BIIB returned +64.7% against AMGN's +54.7%.
| AMGN | BIIB | |
|---|---|---|
| Last close | $432.42 | $218.50 |
| Market cap | $236.3B | $32.7B |
| P/E (FY) | 30.7× | 25.2× |
| P/S | 6.4× | 3.3× |
| EV/EBITDA | 19.8× | — |
| Operating margin | 24.7% | 28.7% |
| Net margin | 21.0% | 13.1% |
| Return on equity | 106.1% | — |
| Sales growth (3y) | +11.8% | -0.9% |
| EPS growth (3y) | +5.5% | -25.0% |
| Dividend yield | 2.2% | — |
| 1-year return | +54.7% | +64.7% |
Screener snapshot — prices as of 2026-08-28. Each side's last close is the most recent session the snapshot holds for that company, which can be an earlier one, and its 1-year return is measured to that close. Market caps struck on 2026-08-27. Last close, market cap and the 1-year return are price figures; every other row is computed over the company's latest filed fiscal year — FY2025 (ended 2025-12-31) for both. A return on equity past ±100% — AMGN at 106.1% — divides earnings by an average filed equity base smaller in magnitude than the earnings themselves; the two columns are not on one scale. — not published for this company. A ratio goes unpublished for more than one reason: a component the calculation needs is not on file, the filing does not tag the line it is read from, or the calculation is not defined on the filed basis — EV/EBITDA is not printed on non-positive EBITDA, and return on equity is not computed on a zero or negative equity base.
Who holds them, and who has traded them
| AMGN | BIIB | |
|---|---|---|
| Institutional holders (13F) | 3,107 | 997 |
| Insider buyers − sellers (180d) | -1 | — |
| Congressional trades disclosed (180d) | 4 | 6 |
| Executive-branch officials on file — trades disclosed (180d) | 11 | 3 |
Counts only. The congressional figures count transactions dated in the trailing 180 days and disclosed in STOCK Act periodic transaction reports; amounts are filed as ranges and are never summed. The executive-branch figures count the same window of transactions, and they are scoped to one roster. The officials OGE posts for direct download. Insider buyers − sellers counts distinct people filing open-market Form 4 purchases minus distinct people filing open-market sales over the trailing 180 days, capped at ±5. — no open-market Form 4 purchases or sales in the window.
AMGN vs BIIB: common questions
- Is AMGN bigger than BIIB?
- AMGN carries the larger market cap — $236.3B against $32.7B, both struck on 2026-08-27.
- Which trades at a higher P/E, AMGN or BIIB?
- AMGN, at a fiscal-year 30.7× against 25.2× for BIIB. Both are price ÷ latest full-year diluted earnings per share, not a trailing-twelve-month P/E.
- How have AMGN and BIIB performed over the past year?
- BIIB returned +64.7% and AMGN +54.7%, measured on the trailing calendar year to the last close.
- How many institutions hold AMGN and BIIB?
- 3,107 13F filers report a position in AMGN and 997 in BIIB, on the latest quarter in the panel.
- Are AMGN and BIIB in the same industry?
- Both are filed with the SEC under Biological Products, (No Diagnostic Substances), which is the classification this pairing is built on.
AMGN overview → · BIIB overview → · AMGN institutional ownership → · BIIB institutional ownership → · Congress and AMGN → · Congress and BIIB → · Executive branch and AMGN → · Executive branch and BIIB →
More in Biological Products, (No Diagnostic Substances): AMGN vs EXEL · AMGN vs GILD · AMGN vs HALO · AMGN vs NBIX
Stock comparisons lists every pair this site publishes.
Source: SPZCO — https://spzco.com/vs/amgn-vs-biib